SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Pavelka Karel)
 

Sökning: WFRF:(Pavelka Karel) > Body mass does not ...

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the “pan-European registry collaboration for abatacept (PANABA)

Iannone, Florenzo (författare)
University of Bari Aldo Moro
Courvoisier, Delphine S. (författare)
Geneva University Hospital
Gottenberg, Jacques Eric (författare)
University Hospital Of Strasbourg
visa fler...
Hernandez, Maria Victoria (författare)
Hospital Clínic of Barcelona
Lie, Elisabeth (författare)
Diakonhjemmet Hospital
Canhão, Helena (författare)
University of Lisbon
Pavelka, Karel (författare)
University Hospital Motol
Hetland, Merete Lund (författare)
University of Copenhagen,Glostrup Hospital
Turesson, Carl (författare)
Lund University,Lunds universitet,Internmedicin - epidemiologi,Forskargrupper vid Lunds universitet,Internal Medicine - Epidemiology,Lund University Research Groups,Skåne University Hospital
Mariette, Xavier (författare)
University of Paris-Saclay
Choquette, Denis (författare)
University Of Montreal Health Center (CRCHUM)
Finckh, Axel (författare)
Geneva University Hospital
visa färre...
 (creator_code:org_t)
2016-12-14
2017
Engelska 7 s.
Ingår i: Clinical Rheumatology. - : Springer Science and Business Media LLC. - 0770-3198 .- 1434-9949. ; 36:4, s. 773-779
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Some evidences suggest that obesity impairs the effectiveness of TNF inhibitors. We examined the impact of body mass index (BMI) on the clinical effectiveness of abatacept in rheumatoid arthritis (RA) patients. This is a pooled analysis of 10 prospective cohorts of RA patients. All patients with available BMI were included in this study. The primary endpoint was drug retention of abatacept in the different BMI categories. Multivariable Cox regression was used to estimate hazard ratios (HRs) for drug discontinuation. A secondary endpoint was EULAR/LUNDEX response rates at 6/12 months. Of the 2015 RA patients initiating therapy with IV abatacept, 380 (18.9%) were classified as obese. Obese patients had more functional disability, and were less often RF positive. The median abatacept retention time was 1.91 years for obese RA patients compared to 2.12 years for non-obese patients (p = 0.15). The risk of abatacept discontinuation was not significantly different for overweight (HR 1.03 (95% CI 0.89–1.19)), or for obese (HR 1.08 (95% CI 0.89–1.30)) compared to normal-weight patients. Rheumatoid factor positivity reduced the risk of abatacept discontinuation (HR 0.83 (95% CI 0.72–0.95)), while previous biologic therapy was positively associated with drug interruption (HRs increasing from 1.68 to 2.16 with the line of treatments). Obese and non-obese patients attained similar rates of EULAR/LUNDEX clinical response at 6/12 months. Drug retention and clinical response rates to abatacept do not seem to be decreased by obesity in RA patients.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Reumatologi och inflammation (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Rheumatology and Autoimmunity (hsv//eng)

Nyckelord

Abatacept
Body mass index
Drug survival
Rheumatoid arthritis

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy